Krensavage Asset Management, LLC Eagle Pharmaceuticals, Inc. Transaction History

Krensavage Asset Management, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$15.21 - $22.88 $11,726 - $17,640	-771 Reduced 0.68%	112,666 $1.78 Million
Q2 2023 Aug 11, 2023	SELL	$17.74 - $31.87 $5,321 - $9,561	-300 Reduced 0.26%	113,437 $2.21 Million
Q1 2023 May 15, 2023	SELL	$25.06 - $34.09 $27,265 - $37,089	-1,088 Reduced 0.95%	113,737 $3.23 Million
Q4 2022 Feb 15, 2023	SELL	$24.98 - $39.77 $156,324 - $248,880	-6,258 Reduced 5.17%	114,825 $3.36 Million
Q3 2022 Nov 14, 2022	BUY	$26.42 - $47.12 $1,822 - $3,251	69 Added 0.06%	121,083 $3.2 Million
Q2 2022 Aug 16, 2022	BUY	$41.26 - $51.35 $256,926 - $319,756	6,227 Added 5.42%	121,014 $5.38 Million
Q1 2022 May 17, 2022	BUY	$44.58 - $52.6 $370,014 - $436,580	8,300 Added 7.79%	114,787 $5.68 Million
Q4 2021 Feb 15, 2022	SELL	$45.82 - $56.9 $58,924 - $73,173	-1,286 Reduced 1.19%	106,487 $5.42 Million
Q3 2021 Nov 16, 2021	BUY	$43.79 - $55.78 $1.62 Million - $2.06 Million	36,969 Added 52.21%	107,773 $6.01 Million
Q2 2021 Aug 13, 2021	BUY	$36.86 - $44.5 $2.61 Million - $3.15 Million	70,804 New	70,804 $3.03 Million

8.6M

100

Ticker EGRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 13,015,900
Market Cap $7.81M
Description
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...

Get notified when there are updates to the investment portfolio of Krensavage Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Krensavage Asset Management, LLC with notifications on news.